Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs

P. David Charles, Bimal B. Padaliya, William J. Newman, Chandler E. Gill, Cassondra D. Covington, John Y. Fang, Stephanie A. So, Michael G. Tramontana, Peter E. Konrad, Thomas L. Davis

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalParkinsonism and Related Disorders
Volume10
Issue number8
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Antiparkinson Agents
Subthalamic Nucleus
Deep Brain Stimulation
Costs and Cost Analysis
Economic Inflation
Therapeutics

Keywords

  • Antiparkinsonian medications
  • Cost analysis
  • Deep brain stimulation
  • Parkinson's disease
  • Subthalamic nucleus

ASJC Scopus subject areas

  • Aging
  • Clinical Neurology
  • Neurology

Cite this

David Charles, P., Padaliya, B. B., Newman, W. J., Gill, C. E., Covington, C. D., Fang, J. Y., ... Davis, T. L. (2004). Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism and Related Disorders, 10(8), 475-479. https://doi.org/10.1016/j.parkreldis.2004.05.006

Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. / David Charles, P.; Padaliya, Bimal B.; Newman, William J.; Gill, Chandler E.; Covington, Cassondra D.; Fang, John Y.; So, Stephanie A.; Tramontana, Michael G.; Konrad, Peter E.; Davis, Thomas L.

In: Parkinsonism and Related Disorders, Vol. 10, No. 8, 12.2004, p. 475-479.

Research output: Contribution to journalArticle

David Charles, P, Padaliya, BB, Newman, WJ, Gill, CE, Covington, CD, Fang, JY, So, SA, Tramontana, MG, Konrad, PE & Davis, TL 2004, 'Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs', Parkinsonism and Related Disorders, vol. 10, no. 8, pp. 475-479. https://doi.org/10.1016/j.parkreldis.2004.05.006
David Charles, P. ; Padaliya, Bimal B. ; Newman, William J. ; Gill, Chandler E. ; Covington, Cassondra D. ; Fang, John Y. ; So, Stephanie A. ; Tramontana, Michael G. ; Konrad, Peter E. ; Davis, Thomas L. / Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. In: Parkinsonism and Related Disorders. 2004 ; Vol. 10, No. 8. pp. 475-479.
@article{31e6ed8b5dca4e3cb064144cc44e7f73,
title = "Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs",
abstract = "This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32{\%} reduction in APMED costs after 1 year and a 39{\%} reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.",
keywords = "Antiparkinsonian medications, Cost analysis, Deep brain stimulation, Parkinson's disease, Subthalamic nucleus",
author = "{David Charles}, P. and Padaliya, {Bimal B.} and Newman, {William J.} and Gill, {Chandler E.} and Covington, {Cassondra D.} and Fang, {John Y.} and So, {Stephanie A.} and Tramontana, {Michael G.} and Konrad, {Peter E.} and Davis, {Thomas L.}",
year = "2004",
month = "12",
doi = "10.1016/j.parkreldis.2004.05.006",
language = "English (US)",
volume = "10",
pages = "475--479",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs

AU - David Charles, P.

AU - Padaliya, Bimal B.

AU - Newman, William J.

AU - Gill, Chandler E.

AU - Covington, Cassondra D.

AU - Fang, John Y.

AU - So, Stephanie A.

AU - Tramontana, Michael G.

AU - Konrad, Peter E.

AU - Davis, Thomas L.

PY - 2004/12

Y1 - 2004/12

N2 - This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.

AB - This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32% reduction in APMED costs after 1 year and a 39% reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.

KW - Antiparkinsonian medications

KW - Cost analysis

KW - Deep brain stimulation

KW - Parkinson's disease

KW - Subthalamic nucleus

UR - http://www.scopus.com/inward/record.url?scp=20844458091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844458091&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2004.05.006

DO - 10.1016/j.parkreldis.2004.05.006

M3 - Article

VL - 10

SP - 475

EP - 479

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 8

ER -